AGILON HEALTH (AGL)
Health Care · Healthcare Services / Managed Care · NYSE
Agilon health partners with primary care physicians to modernize their practices and shift them toward value-based care models for Medicare Advantage populations.
What AGILON HEALTH does
agilon health, inc. operates a healthcare platform that partners with primary care physicians to transition them from a fee-for-service model to a value-based care model. The company provides the technology, capital, and management support necessary for these physicians to manage the total cost of care for their Medicare Advantage patients. By enabling physicians to focus on outcomes rather than volume, agilon seeks to improve health quality and reduce medical costs.
Themes: value-based care, Medicare Advantage, physician enablement, population health management
Fundamentals
- Price$91.72 as of 2026-10-20 close
- Market cap$1.5B as of 2026-07-30 (share count; price 2026-10-20)
- 1-year return+270.6% 2025-10-20 close $24.75 → 2026-10-20 close $91.72
- P/En/a negative earnings
- Net margin-6.6% FY2025, SEC XBRL
- ROE-308.8% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.13 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)-2.1% FY2025, SEC XBRL
- Revenue CAGR (3y)+35.4% SEC XBRL
- Beta0.71 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How AGL compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1.5B | $12M | $18M | -$57M† | $3M† |
| Q1 FY2026 2026-03-31 | $1.4B | $4M | $49M | $24M | $3M |
| Q4 FY2025 2025-12-31 | $1.6B† | -$194M† | -$189M† | -$21M† | $3M† |
| Q3 FY2025 2025-09-30 | $1.4B | -$131M | -$110M | -$18M† | $3M† |
| Q2 FY2025 2025-06-30 | $1.4B | -$116M | -$104M | -$35M† | $3M† |
| Q1 FY2025 2025-03-31 | $1.5B | -$22M | $12M | -$32M | $4M |
| Q4 FY2024 2024-12-31 | $1.5B† | -$108M† | -$106M† | $16M† | $3M† |
| Q3 FY2024 2024-09-30 | $1.5B | -$134M | -$118M | -$8M† | $4M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$107M
- Total debt$30M borrowings only; leases excluded
- Net debt-$77M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How AGILON HEALTH looks technically
AGILON HEALTH (AGL) is trading 50.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 108 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-09-15, pushing above its recent trading range. It is 31.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 50.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +50.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $88.33 | $88.33 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $61.07 | $61.07 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 72.16. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 108 trading days ago — a "golden cross", a bullish long-term signal | 108 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($77.71 to $94.05) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 85.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $133.04 | $133.04 |
|---|---|---|
| From the 52-week high | it is 31.1% below its 52-week high (its highest price of the past year) | -31.1% |
| Above the 52-week low | it is 1126.2% above its 52-week low (its lowest price of the past year) | +1,126% |
| Below the 52-week high | it is 31.1% below its highest point of the past year | 31.1% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-15, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $1120.75 (set on 2021-06-18) | $1120.75 |
| Given back of the 52-week move | over the past year its closes ranged ($7.91 to $129.84), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $50.59 to $54.49. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 31.3% |
| From the all-time high | it is 91.8% below its all-time high | -91.8% |
| Nearest price level | it is trading 1.9% below a resistance level at $93.50 — a price it turned at twice since 2025-01-30, most recently on 2026-06-25. Since 2024-10-21 it has 6 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.9% |
| All-time low | its lowest closing price on record is $7.48 (set on 2026-03-31) | $7.48 |
| Above the all-time low | it is 1126.2% above its all-time low | +1,126% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 81% of it) | 19th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.95 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.95 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $76.40 and $91.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $76.40 – $83.91 – $91.42 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges above its 200-day average price (50.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Open gap | it gapped 6.7% below the previous close 52 sessions ago and has not traded back through the level it left behind at 107.85 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.7% |
|---|---|---|
| Gap filled | a 2.1% gap down opened on 2026-10-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.75% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.9 percentage points (the stock gained 2.9% while the market gained 1.0%) | +1.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.5 percentage points (the stock lost 24.9% while the market gained 3.6%) | -28.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 215.6 percentage points (the stock gained 224.1% while the market gained 8.5%) | +215.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 256.0 percentage points (the stock gained 270.6% while the market gained 14.6%) | +256.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 17.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -0.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 50% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $61.20 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +49.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $90.03 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | +1.9% |
Price levels it has turned at before
AGL last closed at $91.72 on 2026-10-20. Since 2024-10-21 it has turned at 6 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $93.50 | Resistance | 1.9% above the last close | turned there twice · 2025-01-30 to 2026-06-25 |
| $96.63 | Resistance | 5.3% above the last close | turned there twice · 2025-04-03 to 2026-09-10 |
| $79.78 | Support | 13.0% below the last close | turned there four times · 2024-11-06 to 2026-06-03 |
| $62.31 | Support | 32.1% below the last close | turned there twice · 2025-06-09 to 2025-07-03 |
| $58.56 | Support | 36.1% below the last close | turned there twice · 2024-10-30 to 2024-12-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $72.16.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 7 trading days, since 2026-10-12.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.40 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$115.83 range $85.00 – $146.00; median $115.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGL
- Consensus EPS estimate-$0.73 next reporting period, as of 2026-10-20
- Estimate change, 30 days-$0.09 from -$0.64, on 2026-09-20, 30-day window
- Readings revised upward9% of 11 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Exposure to significant financial risk and volatility associated with medical cost outcomes under value-based care contracts.","Reliance on a limited number of primary care physician partnerships and potential difficulty in expanding the network.","Complex regulatory environment impacting Medicare Advantage payment rates and reimbursement methodologies."]
What changed in the latest 10-Q
AI-assisted comparison of AGL's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Notes:
- The provided newer and older MD&A excerpts are textually identical for the portion supplied. The only apparent difference is the Table of Contents page number (newer: 22, older: 21), which is a pagination artifact rather than a substantive change in MD&A content.
Risk Factors
- Added:
- Newer filing (2026-08-05) includes Exhibit 10.5: Severance Agreement and General Release, dated as of July 17, 2026, by and between agilon health, inc. and Girish Venkatachaliah (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed July 22, 2026). Not present in older filing.
- Removed:
- Older filing (2026-05-06) includes a risk factor titled 'We may be unable to comply with the continued listing requirements of the NYSE...' describing the NYSE minimum share price non-compliance notice dated November 5, 2025, the 1-for-25 reverse stock split effective March 30, 2026, and regaining compliance notice dated May 1, 2026. This risk factor text is not present in the newer filing.
- Older filing (2026-05-06) includes Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, including RSU share issuances on January 1, 2026 (109,562 shares), February 1, 2026 (106,112 shares), and March 9, 2026 (111,656 shares) for total $230,511, and Section 4(a)(2) exemption discussion. Not present in newer filing.
- Older filing (2026-05-06) includes in Item 5. Other Information a paragraph about the NYSE non-compliance notice dated November 5, 2025, the 1-for-25 reverse stock split on March 30, 2026, and regaining compliance on May 1, 2026. Not present in newer filing's Item 5.
- Older filing (2026-05-06) includes Exhibit 10.1: Amended and Restated Employment Agreement, dated as of January 1, 2026, by and between Jeffrey Schwaneke and Agilon Health Holdings, Inc. and agilon management, inc. Not present in newer filing.
- Older filing (2026-05-06) includes Exhibit 10.2: Employee Restricted Stock Unit Agreement, dated as of January 1, 2026, by and between Jeffrey Schwaneke and agilon health, inc. Not present in newer filing.
- Older filing (2026-05-06) includes Exhibit 10.7: Third Amendment to Credit Agreement, dated as of February 10, 2026, among agilon health, inc., agilon health management, inc., Agilon Health Intermediate Holdings, Inc., the Subsidiary Guarantors party thereto, the Lenders and Issuers from time to time party thereto and J.P. Morgan Chase Bank, N.A. Not present in newer filing.
- Older filing (2026-05-06) includes Exhibit 10.8: Parent Guaranty, dated as of February 10, 2026, between agilon health, inc., in favor of J.P. Morgan Chase Bank, N.A. Not present in newer filing.
- Reworded:
- Risk Factors (Item 1A): Older filing (2026-05-06) states 'The information presented below updates, and should be read in conjunction with, the risk factors and information disclosed in our Annual Report on Form 10-K. Except as set forth below, there have been no material changes to the risk factors disclosed in the Form 10-K.' Newer filing (2026-08-05) states 'There have been no material changes to the risk factors disclosed in that Form 10-K.' and omits the updating language and the additional risk factor that followed in the older filing.
- Item 5. Other Information: Older filing (2026-05-06) covers 'During the three months ended March 31, 2026' regarding Rule 10b5-1 trading arrangements; newer filing (2026-08-05) covers 'During the three months ended June 30, 2026' for the same statement.
- Notes:
- Newer filing excerpt includes Items 5, 6, and Signatures beyond the Risk Factors section; older filing excerpt similarly includes Items 2, 5, 6, and Signatures. Changes outside Item 1A are included where observable.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AGL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AGL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,954,823
- Reported value $209,517,899
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AGL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AGL had 1,008,702 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AGL had 6.01% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.84 days to cover at the same settlement.
- Reported short interest (shares) 1,008,702
- Short interest (% of shares outstanding) 6.01%
- Prior settlement (shares) 1,050,591
- Reported change -3.99%
- Days to cover (reported) 3.84
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Oak Street Health (CVS)
- Privia Health (PRVA)
- CareMax (CMAX)
- Humana (HUM)
- UnitedHealth Group (UNH)
- Cigna (CI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGL vs…
AGILON HEALTH is found in…
AGL ranks in…
Frequently asked questions
What does AGILON HEALTH (AGL) do?
agilon health, inc. operates a healthcare platform that partners with primary care physicians to transition them from a fee-for-service model to a value-based care model. The company provides the technology, capital, and management support necessary for these physicians to manage the total cost of care for their Medicare Advantage patients. By enabling physicians to focus on outcomes rather than volume, agilon seeks to improve health quality and reduce medical costs.
What sector is AGILON HEALTH (AGL) in?
AGILON HEALTH (AGL) is classified in the Health Care sector. Its industry is Healthcare Services / Managed Care. It trades on NYSE.
Who are AGILON HEALTH's (AGL) competitors?
Notable peers of AGILON HEALTH (AGL) include Oak Street Health, Privia Health, CareMax, Humana and UnitedHealth Group. This peer set is informational only — not financial advice.
Is AGILON HEALTH (AGL) overbought or oversold right now?
AGILON HEALTH (AGL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.